



Interim Guidance on the Use of Rapid Antigen tests for COVID-19 Response


ASLM

AFRICAN SOCIETY FOR LABORATORY MEDICINE

ADVANCING THE LABORATORY PROFESSION AND NETWORKS IN AFRICA

COVID-19 rapid antigen testing

COVID-19: The pandemic



COVID-19: The testing need

- Diagnostic testing for SARS-CoV2 is vital for the control of COVID-19 pandemic in Africa
- Test all individuals with symptoms consistent with COVID-19 as quickly as possible.
- This is heavily dependent on easy and timely access to testing
- Diagnosis gap between the rRT-PCR testing capacity in laboratories and the number of suspected cases to be tested continues to be a major issue
- Access to these molecular tests and the provision of results in a clinically relevant timely manner remains a challenge
- COVID-19 rapid antigen tests (COVID-19 Ag-RDTs) are an easy-to-use alternative to NAAT, which can provide a result in 15-30 minutes and can be used at point-of-care

The testing menu has many options, Antigen tests are best suited for **widely accessible**, rapid screening at point of care

		PCR tests	Antigen tests	Impact of antigen tests
Availability of supply		<ul style="list-style-type: none"> Limited supply of automated PCR tests available to African countries 	<ul style="list-style-type: none"> Available in large supplies, sufficient to fulfill the entire testing demand 	<ul style="list-style-type: none"> Increases supply in the market to meet demand for resource-light COVID-19 diagnostic tests in African countries
Cost		<ul style="list-style-type: none"> Cost per test of ~\$10-20 USD is a significant limitation given funding constraints in low-and-middle income countries 	<ul style="list-style-type: none"> ≤ \$5 USD each, antigen tests are 3-4x cheaper than PCR tests, with additional savings on sample transport 	<ul style="list-style-type: none"> Allows countries to purchase more tests with limited funding available, leading to increased access to testing
Coverage		<ul style="list-style-type: none"> Typically conducted in centralized laboratories, creating a barrier to access outside of urban areas 	<ul style="list-style-type: none"> As point-of-care tests, can be flexibly deployed in all settings 	<ul style="list-style-type: none"> Supports decentralization of testing to lower-level health facilities and remote regions, enabling increased testing coverage
Turnaround time		<ul style="list-style-type: none"> Average test result return of ~2-5 days prevents effective and timely response^{1,2} 	<ul style="list-style-type: none"> Tests results in 10-20 minutes 	<ul style="list-style-type: none"> Enable immediate decisions to be taken for patient care, contact tracing, isolation and treatment

1. Mapping of TAT across 10 high volume Sub-Saharan African countries: CHAI analysis, August 2020.

2. TAT of >2 days has a little to no impact on reducing transmission: Ferretti et al., Science 368, eabb6936 (2020).

COVID-19 antigen testing: Support systems



Comprehensive training and supervision



Engagement in quality assurance activities



Establishing clear roles for both COVID-19 Ag RDTs and RT-PCR within the new testing strategy



Capturing and integrating testing data to inform evidence-based decisions



Continuously learning and updating testing strategies

COVID-19 antigen testing

- Antigen testing would reduce testing cost and could double the testing program within existing budgets
- Antigen-based screening programs would allow for greater movement of goods and people by identify infectious asymptomatic cases
- Achieving true herd immunity with vaccinations may take >2 years and thus diagnostics and particularly antigen testing would be needed for managing of the epidemic

COVID-19: Guidance on antigen testing



Interim Guidance on the Use of Rapid Antigen tests for COVID-19 Response

**Use case scenarios for
COVID-19 antigen
tests.**

**Associated testing
algorithms for COVID-19
antigen tests.**